PFAS contamination in tap water: Target and suspect screening of zwitterionic, cationic, and anionic species across Canada and beyond.

This study investigated the occurrence of perfluoroalkyl and polyfluoroalkyl substances (PFAS), including anionic, cationic, and zwitterionic compounds, in drinking water. Between 2021-2023, an expanded list of 76 target PFAS was screened in tap water samples mainly from Canada, but also including tap water samples from the Eastern United States, Mexico, South America (Argentina), the Caribbean (Dominican Republic, Cuba), Africa (Algeria, Cameroon, Central African Republic, Morocco, Rwanda, Tunisia), Europe (France, Greece, Italy, Spain, and the United Kingdom) and Asia (Japan, Vietnam, Iran, and Türkiye). An additional ∼ 200 suspect-target PFAS were screened using high-resolution Orbitrap mass spectrometry.

Erratum: Lipid nanoparticle encapsulation of a Delta spike-CD40L DNA vaccine improves effectiveness against Omicron challenge in Syrian hamsters.

[This corrects the article DOI: 10.1016/j.omtm.

Zwitterionic, cationic, and anionic PFAS in freshwater sediments from AFFF-impacted and non-impacted sites of Eastern Canada.

Zwitterionic, cationic, and anionic per- and polyfluoroalkyl substances (PFAS) were investigated in freshwater sediments of Canada, including sites impacted by aqueous film-forming foams (AFFFs). The first step of the project involved optimizing the extraction method with equilibrated sediment-water-AFFF samples. The analytical method had acceptable linearity, accuracy, and precision in the sediment matrix, and was further validated with NIST SRM 1936.

Mucosal SARS-CoV-2 S1 adenovirus-based vaccine elicits robust systemic and mucosal immunity and protects against disease in animals.

Unlabelled: The COVID-19 pandemic has emphasized the importance and need for accessible safe, effective, and versatile vaccine platforms. While approved SARS-CoV-2 vaccines have been instrumental in saving lives and reducing healthcare and economic burdens, the induction of mucosal immunity remains an unmet need. Here, we engineered and evaluated a non-replicating adenovirus 5 (rAd5)-based vaccine expressing the SARS-CoV-2 S1 subunit (rAd5-SARS2-S1).